[HTML][HTML] Lutetium-labelled peptides for therapy of neuroendocrine tumours
BLR Kam, JJM Teunissen, EP Krenning… - European journal of …, 2012 - Springer
Abstract Treatment with radiolabelled somatostatin analogues is a promising new tool in the
management of patients with inoperable or metastasized neuroendocrine tumours …
management of patients with inoperable or metastasized neuroendocrine tumours …
[HTML][HTML] Radionuclides for targeted therapy: physical properties
C Stokke, M Kvassheim, J Blakkisrud - Molecules, 2022 - mdpi.com
A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …
inception in 1925, has had as its principal objective the development of internationally …
[HTML][HTML] Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility …
U Garske-Román, M Sandström, K Fröss Baron… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
yielded promising results. This prospective study investigated the feasibility of dosimetry of …
[HTML][HTML] Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European journal of …, 2022 - Springer
Abstract Purpose Radionuclide therapy with 177Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment
M Sandström, U Garske-Román… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The organs at risk in radionuclide therapy with 177Lu-octreotate are the bone marrow and
the kidneys. The primary aim of this study was to develop an individualized dosimetry …
the kidneys. The primary aim of this study was to develop an individualized dosimetry …
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning
M Cremonesi, ME Ferrari, L Bodei, C Chiesa… - European journal of …, 2018 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y-labelled and 177 Lu-
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …
labelled peptides is an effective strategy for the treatment of metastatic/nonresectable …
[HTML][HTML] Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
H Bergsma, MW Konijnenberg… - European Journal of …, 2016 - Springer
Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur,
particular in PRRT with 90 Y-labelled somatostatin analogues. Risk factors have been …
particular in PRRT with 90 Y-labelled somatostatin analogues. Risk factors have been …
[BOOK][B] X-ray Imaging: fundamentals, industrial techniques and applications
HE Martz, CM Logan, DJ Schneberk, PJ Shull - 2016 - taylorfrancis.com
While books on the medical applications of x-ray imaging exist, there is not one currently
available that focuses on industrial applications. Full of color images that show clear …
available that focuses on industrial applications. Full of color images that show clear …
[HTML][HTML] Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
C Kratochwil, L Apostolidis, H Rathke… - European journal of …, 2021 - Springer
Purpose The aim of this retrospective analysis is to estimate the most appropriate single
cycle and cumulative doses of 225Ac-DOTATOC in patients treated for somatostatin …
cycle and cumulative doses of 225Ac-DOTATOC in patients treated for somatostatin …